Single blind, randomized, crossover, repeated dose, pharmacokinetic and pharmacodynamic interaction study of CHF 4226 HFA and Extra-fine BUD HFA in asthmatic patients

Chiesi Farmaceutici S.p.A.0 个研究点目标入组 36 人开始时间: 2006年6月15日最近更新: 2014年10月7日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Chiesi Farmaceutici S.p.A.
入组人数: 36

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Patients with mild or moderate asthma and a FEV1= 70% predicted stabilized on inhaled corticosteroids or combination of inhaled steroids and long acting beta2 agonists.
•2.Written informed consent obtained.
•3.Male or female patients aged = 18 years and =70.
•4.Patients with a documented positive response to the reversibility test (i.e. FEV1 increase = 15% and 200mL from baseline value after 2 puffs of 100 mg of inhaled salbutamol pMDI) within the 12 months preceding the screening visit or performed at screening visit after a wash-out of 2 days for patient asthma treatment (inhaled corticosteroids or combination of inhaled steroids and long acting beta2 agonists) or a documented positive response to the methacholine challenge test.
•5.Non-smokers or ex-smokers <5 pack-year [e.g. less than 1 pack cigarettes (i.e. 20 cigarettes) per day for 5 years or 2 packs cigarettes per day for 2.5 years] and having stopped smoking >1 year.
•6.Patients with a co-operative attitude and ability to be trained to correctly use the pMDI.
•7.Patients with no clinically relevant abnormalities in physical examination, vital signs measurements and ECG
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1.Pregnant or lactating females or females at risk of pregnancy, i.e. those not making use of an effective contraceptive method.
•2.Patients not able to carry out pulmonary function testing.
•3.Diagnosis of COPD as defined by the current GOLD guidelines.
•4.History of near fatal asthma.
•5.History of significant seasonal variation of asthma.
•6.Hospitalization due to asthma in the 8 weeks prior screening.
•7.Patients with asthma exacerbation (see definition in Appendix 8) within the 4 weeks prior to screening visit.
•8.Patients with more than 3 episodes of asthma exacerbation (see definition in Appendix 8) within the 6 months prior to screening visit.
•9.Patients with an uncontrolled cardiovascular (e.g., uncontrolled hypertension), respiratory, hematologic, immunologic, renal, neurologic, hepatic, endocrine (e.g., uncontrolled diabetes mellitus) or other disease, or any condition that might, in the judgment of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study.
•10.Patients with a history of coronary artery disease, cerebrovascular disease, or cardiac arrhythmias.
•11.Patients with a laboratory value (i.e. hematology, blood chemistry, urinalysis, ECG) indicating an uncontrolled concomitant disease.
•12.Patients with a serum potassium value = 3.5 mEq/L or >5.5mEq/L and/or a fasting serum glucose value = 140 mg/dL.
•13.Patients treated with any non-permitted concomitant medication (see list in 5.13).
•14.Patients with a QTc interval (Bazett’s formula) at the screening visit ECG test >450 msec.
•15.Cancer or any other chronic disease with poor prognosis and /or affecting patient status.
•16.History or presence of drug addiction (positive drug screen) or excessive use of alcohol (weekly intake in excess of 28 units alcohol; one unit alcohol equals a glass of beer, a glass of wine or a measure of spirits), or excessive consumption of xanthine containing substances (daily intake in excess of 5 cups of coffee, tea, cola, etc) or psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the patient to comply with the protocol requirements
•17.Allergy, sensitivity or intolerance to beta2-aderenergic agonists and/or budesonide and/or study drug formulation ingredients.
•18.Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
•19.Patients who received any investigational new drug within the last 8 weeks prior to the screening visit.
•20.Blood donation (450 mL or more) or significant blood loss less than 12 weeks before the first intake of study drug.
•21.Positive HIV1 or HIV2 serology.
•22.Hepatitis serology positive for acute or chronic hepatitis B or hepatitis C.
•23.Unsuitable veins for repeated puncture.

研究者

发起方

Chiesi Farmaceutici S.p.A.

相似试验

尚未招募

1 期

PK/PD Study of InsuBiomm N (NPH Insulin) in Comparison to Humulin N in Type 1 patients (T1DM)Type 1 diabetes mellitus

RBR-8b9npbInstituto de Ciências Farmacêuticas de Estudos e Pesquisas Ltda.

已完成

1 期

Comparative assessment in healthy male volunteers under fasting conditions of the absorption and pharmacokinetics of a test formulation of isotretinoin capsule against an innovator isotretinoin capsule in a pilot studyAcne

ACTRN12616000663459Zenith Technology Corporation Limited16

进行中（未招募）

1 期

EUCTR2014-005047-40-BGSanofi-Aventis AG120

进行中（未招募）

1 期

Study in Subjects with Asthma to Compare the Bronchodilatoric Effects of Salmeterol (at two different doses) and Fluticasone Propionate when Taken Via a Novel Inhaler Device (PulmoJet®) Compared to the Seretide Diskus® InhalerMild to moderate asthmaMedDRA version: 17.1Level: LLTClassification code 10003565Term: AsthmaticSystem Organ Class: 100000004855

EUCTR2014-005047-40-DESanofi-Aventis AG120

进行中（未招募）

1 期

EUCTR2014-005047-40-GBSanofi-Aventis AG240